UK Corporate Profitability And Pharmaceuticals

10 February 1997

The profitability of UK companies has finally recovered from therecession, three years after it supposedly ended, according to the global information services group, CCN Group's latest Corporate Health Check of UK firms. Corporate profitability had been stuck at around 11.5% since early 1995, but in the third quarter of 1996 it moved ahead to 12.1% as orders and manufacturing output picked up again, along with a strong upturn in consumer confidence.

"In real terms, allowing for inflation," commented Jo Howard of the CCN Group, "UK profitability has returned to the highest level since before the recession. The real return on capital employed in British industry was 10% in the third quarter, compared with 7.1% in 1991, before the recession began to bite."

This encouraging performance looks likely to be sustainable in 1997. Manufacturing growth in October was the strongest for 18 months, and there was a pick-up in consumer demand fuelled by lower taxes, interest rate cuts, higher incomes and rising employment.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight